title: Ambulatory management of varicella-zoster virus infection in immunocompromised cancer patients.
abstract: Immunocompromised patients with varicella-zoster virus (VZV) infection are at greater risk for dissemination and the development of complications than immunocompetent individuals. Consequently, they are generally hospitalized in strict isolation rooms and treated with parenterally administered acyclovir. Although effective, this approach is expensive and creates logistic difficulties in the hospital. We treated 38 immunosuppressed cancer patients presenting to our ambulatory treatment center with VZV infections with intravenous acyclovir (500 mg/m2 8-hourly) in an ambulatory/home setting. Patients were monitored for success or failure of therapy, progression of infection, development of complications or drug toxicity, and satisfaction/compliance with therapy. Most patients (33, or 87%) responded to therapy. Among the failures, 2 patients had progressive VZV infection, 2 were hospitalized due to renal toxicity, and 1 developed a superinfection. All patients eventually responded and there were no deaths on this study. Two patients relapsed within 1 month of initial response. Both responded to retreatment with acyclovir, without hospitalization. The median duration of parenteral therapy with acyclovir was 7.5 days. Seven patients (18%) had to be switched to oral acyclovir (800 mg, 5 times a day) before complete response, owing to problems with venous access. All 7 completed therapy successfully. Overall, patients expressed a high level of satisfaction with outpatient therapy, and there were no instances of noncompliance or patient requests for withdrawal from study. The results of this study indicate that VZV infections in clinically stable immunosuppressed cancer patients are relatively benign and do not require hospitalization. Parenterally administered acyclovir in an ambulatory setting is effective therapy for such infections.
authors.affiliation: Ambulatory and Supporting Care Oncology Research Program (ASCORP), University of Texas, M.D. Anderson Cancer, Houston 77030, USA.
authors.forename: K V
authors.initials: KV
authors.lastname: Rolston
authors.forename: E
authors.initials: E
authors.lastname: Manzullo
authors.forename: L
authors.initials: L
authors.lastname: Elting
authors.forename: S
authors.initials: S
authors.lastname: Frisbee-Hume
authors.forename: S
authors.initials: S
authors.lastname: Rodriguez
authors.forename: E B
authors.initials: EB
authors.lastname: Rubenstein
mesh_terms: D000212:Acyclovir / Q000191:economics / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000191:economics; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D005260:Female; D006562:Herpes Zoster / Q000188:drug therapy* / Q000276:immunology; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D016867:Immunocompromised Host; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000276:immunology; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000212:Acyclovir